Navigation Links
Cardiogenesis Announces Successful Educational Symposium at Society of Thoracic Surgeons Meeting in San Francisco
Date:1/28/2009

a href="http://www.cardiogenesis.com/" target="_new">http://www.cardiogenesis.com. Cardiogensis also maintains a website where patients suffering from angina can learn more about the TMR procedure at http://www.heartofnewlife.com.

Safe Harbor Statement

With the exception of historical information, the statements set forth above include forward-looking statements. Any forward-looking statements in this news release related to the possible effectiveness of the Company's technologies and the effect of such technologies on the Company's sales, profitability, the adoption of its technology and products and FDA clearances are based on current expectations and beliefs and are subject to numerous risks and uncertainties, many of which are outside the Company's control, that could cause actual results to differ materially. Factors that could affect the accuracy of these forward-looking statements include, but are not limited to: any inability by the Company to sustain profitable operations or obtain additional financing on favorable terms if and when needed; any failure to obtain required regulatory approvals; failure of the medical community to expand its acceptance of TMR procedures; possible adverse governmental rulings or regulations, including any FDA regulations or rulings; the Company's ability to comply with international and domestic regulatory requirements; possible adverse Medicare or other third-party reimbursement policies or adverse changes in those policies; any inability by the Company to ship product on a timely basis; the Company's ability to manage its growth; the effects of recent disruptions in global credit and equity markets and other adverse economic developments that could adversely affect the market for our products or our ability to raise needed financing; actions by our competitors; and the Company's ability to pr
'/>"/>

SOURCE Cardiogenesis Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cardiogenesis Corporation to Report Third Quarter 2008 Results on November 13th
2. Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C.
3. Cardiogenesis Announces Preliminary Results Combining TMR + Platelet Rich Plasma (PRP)
4. Cardiogenesis Reports First Quarter 2008 Results
5. Cardiogenesis Corporation to Report 2008 First Quarter Results on May 15th
6. Cardiogenesis Corporation Announces Rescheduled Fourth Quarter and Full Year 2007 Earnings Release
7. Cardiogenesis Corporation Reports Delay in Earnings Release and Conference Call
8. Cardiogenesis Corporation to Report 2007 Fourth Quarter and Year-End Results on March 4th
9. Cardiogenesis Receives FDA Approval for PEARL 5.0 Robotic Hand Piece
10. Nuvo Research Announces Successful Completion Of All Pennsaid(R) Studies
11. BD Announces Results for First Fiscal Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... pm EDT): In a Viewpoint published today in the ... team of Boston researchers call for the implementation of ... United States. The researchers from the Friedman School of ... and Boston Children,s Hospital write that policies taxing nearly ... help people make meaningful dietary changes and substantially reduce ...
(Date:9/2/2014)... Friendship Village of Schaumburg is proud to ... contemporary marketing presence and visually solidifies the relationship ... Senior Options,” said Stephen A. Yenchek, president and ... logo, we are making sure that our identity ... families.” , Friendship Village is a retirement community ...
(Date:9/2/2014)... CA (PRWEB) September 02, 2014 On ... on its website titled “Why You Should Wash Your ... 80 percent of the global population breathes air considered ... particles of pollution lodge in the skin’s pores destroying ... natural barrier to free radicals that may cause cell ...
(Date:9/2/2014)... 2014 In a large population-based study of ... mild cognitive impairment (MCI) occurred twice more often ... Interestingly, this strong association was only observed in ... (66-80 years) the association vanished. This study is ... . , The concept of MCI describes an ...
(Date:9/2/2014)... The Dream2Walk Foundation along with Gas Monkey Bar and Grill ... Cord Injury Awareness Month featuring full band performances by Zane ... Automotive will be there hosting a Hot Rod, Rat Rod, ... The car show is Pre 1964 only, with a $50.00 ... There will be trophies for top 3 and best of ...
Breaking Medicine News(10 mins):Health News:Taxes and subsidies could encourage healthier diet and lower healthcare costs 2Health News:Friendship Village of Schaumburg In Illinois Announces New Logo 2Health News:Simon Ourian, Kim Kardashian’s Doctor: Air Pollution May Be Aging Your Skin 2Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Gas Monkey Hosts Concert in Dallas Benefiting Dream2Walk Foundation with Linear Automotive 2
... News) --,Concentrating on music can provide enough distraction to ... to a new study. Researchers from the University ... music as a pain reliever on 143 study participants. ... they could identify the tones that stood out. While ...
... HealthDay Reporter , THURSDAY, Dec. 29 (HealthDay News) -- ... crushing depression and crippling anxiety to powerful delusions and hallucinations ... the imagined. And if that weren,t enough, they also ... world perceives their inner struggle. Stigma associated with ...
... In some cases, memory loss among the elderly may be ... strokes, which may not cause any noticeable symptoms, result in ... roughly 25 percent of older adults, the study team noted. ... in the elderly is that it examines silent strokes and ...
... , WEDNESDAY, Dec. 28 (HealthDay News) -- Two new ... by about four months for women with ovarian cancer. ... make a difference in overall survival. One study suggested it ... overall survival between two treatment groups. "The bottom-line results ...
... 2011 revision of the International Standards for the Neurological ... the November 2011 issue of the Journal of ... Steven Kirshblum et al clarifies the modifications to this ... http://www.ingentaconnect.com/content/maney/scm (#6, Nov 2011). ISNCSCI ...
... Dec. 29, 2011) Treating ovarian cancer with the drug ... show the results of an international clinical trial co-led by ... Health Network and Timothy Perren, St James,s Institute of Oncology, ... New England Journal of Medicine, report that the ...
Cached Medicine News:Health News:Even Today, the Stigma of Mental Illness Won't Fade 2Health News:Even Today, the Stigma of Mental Illness Won't Fade 3Health News:'Silent Strokes' Linked to Memory Loss in Elderly: Study 2Health News:Avastin May Help Some With Ovarian Cancer: Studies 2Health News:Avastin May Help Some With Ovarian Cancer: Studies 3Health News:Avastin May Help Some With Ovarian Cancer: Studies 4Health News:JSCM publishes revised International Standards for Neurological Classification of Spinal Cord Injury 2Health News:Ovarian cancer study proves drug delays disease progression, may improve survival 2
(Date:9/2/2014)... September 2, 2014   ... atrial muestran agentes antitrombóticos no utilizados óptimamente para ... -- Las presentaciones de GARFIELD-AF en el ESC ... y los resultados de pacientes en riesgo de ...    Los datos de casi 12.500 ...
(Date:9/2/2014)... September 2, 2014 ... ESC-Kongress 2014 präsentierte GARFIELD-AF-Register bietet einen ... von schlaganfallgefährdeten Patienten in der klinischen ... Daten der nahezu 12.500 ... und unabhängigen Forschungsinitiative zur Untersuchung von ...
(Date:9/2/2014)... , September 2, 2014 ... CONGRESS 2014 provide insight into treatment and outcomes ... clinical practice --   Data from ... Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF), an innovative, ... prevention strategies for atrial fibrillation (AF) patients remain ...
Breaking Medicine Technology:Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 3Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 4Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 5Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 7Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 8Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 9Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 10Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
... NATICK, Mass. and BARCELONA, Spain, May 20 Boston ... results from an analysis of economic and quality of ... SYNTAX trial. The results found that percutaneous coronary ... System was consistently associated with fewer patient hospital days ...
... suggest pirfenidone may provide meaningful clinical benefit in IPF ... safety reported -- Conference Call and Webcast at 9 ... 19 InterMune, Inc. (Nasdaq: ITMN ) ... studies evaluating pirfenidone in patients with idiopathic pulmonary fibrosis ...
Cached Medicine Technology:SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 2SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 3SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 4SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 5Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 2Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 3Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 4Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 5Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 6Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 7Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 8Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 9Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 10Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 11Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 12
For the quantitative in vitro determination of Magnesium in serum, plasma and urine...
The LDH method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of lactate dehydrogenase activity in serum or plasma...
For the quantitative in vitro determination of Lactate Dehydrogenase (LD) in serum and plasma....
For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum....
Medicine Products: